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OBJECTIVES In this study, we examined whether a reconstituted high-density lipoprotein (HDL) utilizing
recombinant apolipoprotein A-IMilano (apo A-IM)/phospholipid complex (PC) could restore
normal endothelial function in hypercholesterolemic apolipoprotein (apo) E-null mice.
BACKGROUND We have previously shown antiatherosclerotic and vasculoprotective effects of recombinant
apo A-IM.
METHODS A perfused vessel preparation was used to examine vascular responses in control wild-type,
untreated, and treated apo E-null mice. Aortic tissue cholesterol content and platelet
aggregation were also measured.
RESULTS Endothelium-dependent vasodilator responses to acetycholine were significantly inhibited in
untreated apo E-null mice compared with control wild-type mice (p  0.001). Treatment of
the mice for five weeks with once every-other-day intravenous bolus injections of apo
A-IM/PC restored endothelium-dependent dilation in a dose-dependent manner (p  0.01
at 80 mg/kg dose). The improvement in endothelial function was associated with a reduction
in aortic cholesterol content and reduced platelet aggregability and occurred despite severe
and persistent hypercholesterolemia. Neither treatment with free protein nor phospholipid
carrier alone produced any significant effects. We performed additional experiments in vitro
in isolated rabbit carotid arteries to compare the effects on lysophosphatidylcholine (LPC)-
induced endothelial dysfunction. Treatment with apo A-IM/PC prevented impairment of
endothelium-dependent vasodilator responses to acetylcholine to a greater degree than either
wild-type apo A-I or plasma-derived HDL.
CONCLUSIONS Our results indicate a rapid improvement in endothelial dysfunction with recombinant apo
A-IM/PC that is associated with mobilization of tissue cholesterol. Taken together with
previously established antiatherosclerotic and antithrombotic effects, these findings suggest
significant vasculoprotective effects with apo A-IM/PC therapy. (J Am Coll Cardiol 2004;
44:1311–9) © 2004 by the American College of Cardiology Foundationp
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meveral lines of evidence suggest a protective effect of
igh-density lipoprotein (HDL) and apolipoprotein (apo)
-I against atherosclerotic vascular disease. Epidemiologic
tudies have demonstrated an inverse relationship between
lasma HDL or apo A-I levels and atherosclerosis (1). More
irectly, attenuation of atherosclerosis by intravenous ho-
ologous HDL has been demonstrated in cholesterol-fed
abbits (2). Furthermore, overexpression of the human apo
-I gene in apo E-null mice prevents atherosclerotic plaque
ormation (3). The protective effects of HDL have been
rimarily attributed to its effect on reverse cholesterol
ransport activity (4). However, evidence showing direct
ssociation of HDL in humans in ameliorating abnormal
ascular reactivity in atherosclerosis (5,6) and ex vivo plate-
et thrombus formation (7) supports the notion that im-
From the Vascular Physiology and Thrombosis Research Laboratory of the
therosclerosis Research Center, Division of Cardiology, Cedars-Sinai Medical
enter, Los Angeles, California; and the David Geffen School of Medicine,
niversity of California, Los Angeles, California.
Manuscript received March 11, 2004; revised manuscript received June 2, 2004,eccepted June 7, 2004.rovement in endothelial function and thrombogenicity
ight also contribute to the beneficial effects of HDL.
Recently, we and others have focused our investigations
n a naturally occurring molecular variant of apo A-I, apo
-IMilano (apo A-IM) characterized by a cysteine-for-
rginine substitution and formation of apo A-IM/A-IM
imers (8). These latter are characterized by a prolonged
irculation time in plasma and a more effective cholesterol
fflux capacity, thereby conferring protection from cardio-
ascular disease despite markedly reduced HDL levels in
uman carriers of this mutation (9,10). A number of animal
tudies from our laboratory and others have demonstrated
ntiatherogenic (11–14), antiproliferative (11,15), antirest-
notic (16), antiplatelet, and antithrombotic (17) properties
f apo A-IM. Most recently, a pilot clinical trial of recom-
inant apo A-IM demonstrated significant and rapid regres-
ion of atherosclerosis in human coronary arteries (18).
In this study, we examined the effects of treatment with
ecombinant apo A-IM/phospholipid complex (PC) on
ndothelium-dependent vasodilator responses in a murine
odel of atherosclerosis, the apo E-null mice. We hypoth-sized that treatment with apo A-IM/PC will attenuate
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Apolipoprotein A-IMilano and Endothelial Function September 15, 2004:1311–9mpairment of endothelium-dependent vasodilator re-
ponses in apo E-null mice.
To compare the protective effects of apo A-IM on
ndothelium-dependent vasodilator responses with apo A-I
ild-type (apo A-IWT) or plasma-derived HDL, we per-
ormed an additional set of experiments in isolated rabbit
arotid arteries in which endothelial dysfunction was in-
uced by incubation with lysophosphatidylcholine (LPC);
PC has been identified as the principal mediator of the
nhibitory effects of oxidized low-density lipoprotein on
ndothelium-dependent vasomotor reactivity (19). We hy-
othesized that LPC-induced inhibition of endothelium-
ependent vasodilation would be prevented by treatment
ith HDL, and that reconstituted HDL using recombinant
po A-IM would exert greater protective effects compared
ith apo A-IWT or plasma-derived HDL.
ETHODS
tudy protocol. Two sets of experiments were performed
s shown in Figure 1. In the first set, recombinant apo A-IM
as administered intravenously in hypercholesterolemic apo
-null mice and descending thoracic aortas harvested for
ascular reactivity studies. In the second set, carotid arteries
ere harvested from New Zealand White rabbits fed a
ormal diet (2 to 3 kg), endothelial dysfunction was induced
n vitro with incubation with LPC, and effects of treatment
gents on LPC-induced impairment of endothelium-
ependent vasodilator responses were examined.
Three groups of mice (Jackson Laboratory, Bar Harbor,
aine) were studied: 1) 5-week-old WT C57BL/6J strain
ice fed a standard rodent chow for 25 weeks (WT, n  5)
ere used as normal control; 2) 5-week-old untreated apo
-null mice (C57BL/6J strain, 18 to 20 g), fed an atherogenic
iet for 25 weeks (ApoE, n 6) were used as hypercholester-
lemic control; 3) 5-week-old apo E-null mice fed an athero-
enic diet for 25 weeks and treated with two doses of apo A-IM
omplexed with the phospholipid carrier, DPPC (1,2-
ipalmitoyl-sn-3-phosphoglycerocholine) in a protein-to-
hospholipid ratio of 1:2.7 by weight (12) and dissolved in 0.5
l saline—20 mg/kg/dose (ApoE  apo A-IM/DPPC 20, n
9) and 80 mg/kg/dose (ApoE apo A-IM/DPPC 80, n
0), or 80 mg/kg/dose free apoA-IM without DPPC (apo
-IM 80, n  5), or 210 mg/kg/dose DPPC alone (n  5).
ach mouse received 18 intravenous injections through the tail
ein on alternate days from 25 to 30 weeks.
Abbreviations and Acronyms
apo  apolipoprotein
apo A-IM  apo A-IMilano
EDNO  endothelium-derived nitric oxide
HDL  high-density lipoprotein
LPC  L--phosphatidylcholine palmitoyl
PC  phospholipid complex
WT  wild-typeBefore euthanasia, mice were anesthetized with enflurane Mnhalation, and 100 to 300 l of blood was obtained from
he retro-orbital plexus in heparin-coated capillaries (Fisher
cientific, Hampton, New Hampshire) and collected for
latelet aggregation, serum total cholesterol, and serum apo
-IM measurements. Serum cholesterol was measured by
nzymatic technique, and the apo A-IM levels were deter-
ined by ELISA as described previously (12). After anes-
hesia, aortas were harvested and the proximal portion of
escending thoracic aorta used for vascular reactivity studies
nd the distal portion used for aortic tissue cholesterol
ontent. Treated mice were euthanized 12 h after the last
njection of apo A-IM. All research involving these animals
as approved by the institutional animal care and use
ommittee and conformed to the Guiding Principles in the
are and Use of Laboratory Animals established by the
ouncil of the American Physiology Society.
solated perfused artery preparation for vascular reactivity
tudies. Whole mounted pressurized vessels with constant
erfusion were used to study vascular responses (20). The
rteries were isolated, removed, and immediately placed in
old (5°C to 10°C) oxygenated modified Krebs solution
NaCI, 118.3 mM; KC1, 4.7 mM; CaCI2, 2.5 mM;
igure 1. Schema of the experimental protocols are shown. In the mice
xperimental protocol (A), three groups of mice were studied: normal
ild-type control, untreated hypercholesterolemic (HC) apolipoprotein
-null mice (ApoE), and treated HC ApoE-null mice. The types of
tudies and treatment interventions are shown. See text for details of rabbit
xperiments (B). Apo A-IM  apolipoprotein A-IMilano; Apo A-IWT 
polipoprotein A-I wilt-type; DMPC  dimyristylphosphatidylcholine;
PPC  1,2-dipalmitoyl-sn-3-phosphoglycerocholine; HDL  high-
ensity lipoprotein; LDL  low-density lipoprotein; LPC  lysophos-
hatidylcholine.gSO4.7H20, 1.2mM; NaHCO3, 25.0 mM; KH2PO4,
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September 15, 2004:1311–9 Apolipoprotein A-IMilano and Endothelial Function.2 mM; dextrose, 11.0 mM). Loose adventitial connective
issue was removed, and 1.0- to 1.5-cm long segments were
ounted between two plastic cannulae and placed in an
rgan bath. Arteries were perfused intraluminally and su-
erfused abluminally with oxygenated modified Krebs solu-
ion by means of a peristaltic pump (Rainin Instrument Col.
nc., Woburn, Massachusetts) at a constant rate of 3.0
l/min. Pressure at the downstream end of the vessel was
aintained at 80 mm Hg throughout the experimental
rotocol. Arterial segments were observed with 40 mag-
ification, and images were displayed with a video camera
ttached to a microscope. Outer diameter of arteries was
ecorded continuously with an optical system utilizing
omputer-assisted edge detection and digital analysis of the
ideo image. This preparation has been described in detail
reviously (20).
rugs. Recombinant apo A-IM and the phospholipid carriers
,2-dipalmitoyl-sn-3-phosphoglycerocholine (DPPC) and
imyristylphosphatidylcholine (DMPC) were supplied by
harmacia-Upjohn (Stockholm, Sweden). The recombinant
po A-IM/DPPC preparation used in the mice studies has
een described previously (12,13). For rabbit studies, DMPC
as complexed with both recombinant apo A-IM and apo
-IWT in a 1:3 molar ratio; apo A-IWT was generously
rovided by Swiss Red Cross (Bern, Switzerland). Plasma
DL was graciously provided by Mohammad Nawab, PhD
UCLA, Los Angeles, California); HDL was isolated from
lood of normal volunteers by sequential ultracentrifugation
ccording to the method of Havel et al. (21) and the protein
ontent determined by the method of Lowry et al. (22). Freshly
repared HDL (final concentration of 5 mg/ml) was kept in
ark under nitrogen at 4°C and used within three weeks.
Phenylephrine hydrochloride, serotonin creatinine sulfate
5-HT), acetylcholine hydrochloride, sodium nitroprusside,
nd L--phosphatidylcholine palmitoyl (LPC) were pur-
hased from Sigma Chemicals Co. (St. Louis, Missouri).
hromboxane A2 mimetic, U46,619, was obtained from
iomol Research Laboratories, Inc. (Plymouth Meeting,
ennsylvania). Phenylephrine, acetylcholine, and sodium
itroprusside were dissolved in deionized water; serotonin
as dissolved in 0.1 N HC1 with 0.1% ascorbic acid;
46,619 was dissolved in ethanol-0.1 M NaHCO3 (1:3,
ol/vol) to make a stock solution. Each agent was then
iluted in modified Krebs solution, aerated with a mixture
f 95% O2 and 5% CO2 immediately before use; LPC was
issolved in chloroform:methanol 1:1 and sonicated for 10
in before addition to baths. To avoid inactivation of
odium nitroprusside by light, the drug and the stock
olution were kept in the dark, and perfusion tubing was
overed by aluminum foil.
ascular reactivity protocol. Vessels were perfused at flow
ate of 3 ml/min and gradually stretched longitudinally to
he approximate in situ length and exposed to repeated
onstrictor (phenylephrine, 1 M) and dilator (acetylcho-
ine, 1 M) stimuli until reproducible responses were
btained (usually 60 min). Vascular responses to agonists cere recorded for about 5 to 7 min until steady-state
esponses were observed. Between each series of interven-
ions, the preparation was washed by changing the perfusate
olution several times with modified Krebs solution, fol-
owed by an equilibration period of 15 to 20 min. Dilator
esponses to intraluminal acetylcholine (endothelium-
ependent agonist) and sodium nitroprusside (endothelium-
ndependent agonist) were examined in arteries preconstricted
ith abluminal 1 M 5-HT (EC80) in mice, or 1 M
henylephrine (EC80) in rabbit, and expressed as percent of
reconstriction (20). Constrictor responses were measured
n quiescent arteries and expressed as percent change from
aseline diameter (20). Baseline diameter of perfused mice
orta and rabbit carotid arteries was 1.4  0.1 mm and 2.9
0.1 mm (mean  SEM), respectively.
The experimental protocol for rabbit carotid arteries is
hown in Figure 1B and composed of initially performing
oncentration- and time-response experiments to determine
he optimal concentration and incubation time to induce
eversible endothelial dysfunction. After measurement of
ilator responses at baseline (control responses), 50 M LPC
as added to the intraluminal perfusate and the arteries
ncubated for 45 to 60 min in a closed-loop system. Dilator
esponses were then measured to confirm the presence of
ndothelial dysfunction (LPC responses); LPC was then
ashed out by perfusing 0.1% albumin dissolved in modi-
ed Krebs solution for 30 to 45 min and dilator responses
epeated (restoration responses). Finally, LPC was added to
he intraluminal perfusate in presence of the following
gents—apo A-IM /DPPC (1 mg/ml), apo A-IWT/DPPC
1 mg/ml), plasma-derived HDL (1 mg/ml), free apo A-IM
1 mg/ml), and free DPPC (300 g /ml), and dilator
esponses measured (intervention responses). Each experi-
ent took an average of 7 h to complete.
ortic tissue cholesterol content. Aortic tissue cholesterol
ontent was determined in the distal half of the descending
horacic aorta using an assay that has been previously
eported (23). Briefly, aortic tissue was homogenized, and
he lipid content was extracted by treatment with chloro-
orm and methanol followed by centrifugation. The ex-
racted lipid was dissolved in ethanol and measured via a
holesterol assay kit (Sigma) utilizing absorbance spectro-
hotometry, and the amount quantified as g/mg tissue.
latelet aggregation. Citrated whole blood samples (100
l) were collected from mice and diluted with an equal
olume of isotonic saline. Collagen-induced (2 g/ml)
hole blood platelet aggregation was measured by im-
edance aggregometry (Chronolog, Havertown, Pennsyl-
ania). Platelet aggregation was measured as the maximal
hange in impedance in ohms at 6 min after the addition
f collagen.
tatistical analysis. Data are presented as mean  SEM.
tatistical comparisons were performed by analysis of vari-
nce, followed by pairwise comparisons by the two-tailed t
est with the Bonferroni correction. A value of p 0.05 was
onsidered statistically significant.
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Apolipoprotein A-IMilano and Endothelial Function September 15, 2004:1311–9ESULTS
ice studies. VASODILATOR RESPONSES. Representative
xamples of concentration-response curves to acetylcholine
nd sodium nitroprusside in the three groups of mice are
hown in Figure 2A and the data quantified in Figure 2B.
cetylcholine produced a concentration-dependent dilation
f aorta in WT mice. Vasodilator responses to acetylcholine
ere significantly inhibited in untreated ApoE mice (p 
.001. vs. WT). Treatment with apo A-IM/DPPC complex
roduced a dose-dependent improvement in endothelium-
ependent vasodilator responses, which was significant at an
0-mg/kg dose (Fig. 2B). Treatment with both free apo
-IM or DPPC alone tended to improve dilator responses,
ut the effects were not significant.
Dilator responses to endothelium-independent agonist
odium nitroprusside were not significantly different in the
igure 2. (A) Original tracings showing vasomotor responses in isolated de
ApoE), and ApoE mice treated with high-dose (80 mg/kg/dose) apo A-IM
DPPC). Dilator responses to intraluminal perfusion of endothelium-d
odium nitroprusside (SNP) were examined in arteries preconstricted with
oncentration response to Ach (top panel) and sodium nitroprusside (bot
iameter of 1.12  0.02 mm. *p  0.001 vs. ApoE, analysis of variance. O
0 (n 10); solid triangles ApoE apo A-IM/DPPC 20 (n 10); ope
n  5); solid circles  ApoE (n  6).ntreated ApoE mice compared with the WT mice (Fig. vB). None of the treatment interventions had any signifi-
ant effects on dilator responses to sodium nitroprusside
Fig. 2B).
ASOCONSTRICTOR RESPONSES. Maximal constrictor re-
ponses to 5-HT (10 M) did not differ significantly
etween the groups (16  2% in WT, 15  1% in ApoE,
7  2% in ApoE  apo A-IM/DPPC 80, 16  1% in
poE  apo A-IM 80, and 15  2% in ApoE  DPPC).
ikewise, maximal constrictor responses to U46,619 (1
M) were not significantly different (19 2% in WT, 20
% in ApoE, 18  2% in ApoE  apo A-IM/DPPC 80, 19
1% in ApoE  apo A-IM 80, and 20  2% in ApoE 
PPC). These data indicate that altered vasomotor re-
ponses in hypercholesterolemic apo E-null mice are con-
ned to impaired endothelium-dependent dilator responses
nd that treatment had no impact on smooth-muscle
ing thoracic arteries from wild-type mice (WT), untreated apo E-null mice
DPPC complex (ApoE  apo A-IM/DPPC 80) and DPPC alone (ApoE
ent agonist, acetylcholine (Ach), and endothelium-independent agonist,
tonin (5-HT, 1 M) administered abluminally. (B) Line plots showing
panel). Values (mean  SEM) are percent change from a preconstricted
ircles  wild-type (n  5); open triangles  ApoE  apo A-IM/DPPC
ares ApoE apo A-IM 80 (n 5); solid diamonds ApoEDPPCscend
ilano/
epend
sero
tom
pen c
n squasoconstrictor activity.
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September 15, 2004:1311–9 Apolipoprotein A-IMilano and Endothelial FunctionERUM CHOLESTEROL AND APO A-IM LEVELS. Serum cho-
esterol levels were significantly elevated in ApoE compared
ith WT control mice. However, the cholesterol levels did
ot differ between the untreated and treated ApoE mice
Fig. 3A). At the time of euthanasia (12 h after last
njection), apo A-IM was detectable in all mice receiving apo
-IM/DPPC complex (276  105 g/ml, n  8), but in
one of the controls. Antibodies against apo A-IM were
etected in the sera of mice receiving apo A-IM treatment
ut in none of the control mice.
LATELET AGGREGATION. Platelet aggregation was
lightly, but significantly, increased in untreated ApoE mice
ompared with WT mice (p  0.05). Treatment with apo
-IM/DPPC produced a significant inhibition of platelet
ggregation at 80 mg/kg dose (p 0.05). None of the other
nterventions produced significant effects on platelet aggre-
ation (Fig. 3B).
ORTIC TISSUE CHOLESTEROL CONTENT. In the untreated
poE mice, the aortic tissue cholesterol content increased
igure 3. Bar graphs showing effects on serum total cholesterol (A) and
ollagen (2 g/ml)-induced whole blood platelet aggregation (B).
latelet aggregation was measured by impedance aggregometry (Chro-
olog, Havertown, Pennsylvania) and data expressed as the maximal
hange in impedance in ohms (ohmsmax) at 6 min after the addition of
ollagen. Values are mean  SEM. *p  0.05; **p  0.001 vs.
poliprotein E (ApoE), analysis of variance. DPPC  1,2-dipalmitoyl-
n-3-phosphoglycerocholine; WT  wild-type.
igure 4. Bar graphs showing effects on aortic tissue cholesterol content (lef
anel). Values are mean SEM. *p 0.001 vs. apoliprotein E (ApoE); **p
ortic tissue cholesterol content and maximal vasodilator responses to
,2-dipalmitoyl-sn-3-phosphoglycerocholine; WT  wild-type.early eight-fold compared with WT mice (Fig. 4). Treat-
ent with apo A-IM/DPPC produced a dose-dependent
eduction in aortic cholesterol content that achieved statis-
ical significance at the higher dose. Treatment with free
po A-IM or DPPC alone produced modest, but nonsignif-
cant, reductions in aortic tissue cholesterol levels (Fig. 4).
here was a significant inverse correlation between aortic
issue cholesterol content and dilator responses to acetyl-
holine (Pearson r  0.88, p  0.05).
abbit studies. As shown in Figure 5, LPC produced a
oncentration- and time-dependent inhibition of dilator
esponses to acetylcholine. An optimal concentration of
0 M LPC produced endothelial dysfunction that was
hort-lived and reversed within 45 min of washout.
rreversible damage was observed at a concentration of
00 M LPC. These findings are consistent with previ-
us observations that submicellar concentrations of LPC
50 M) induce reversible endothelial dysfunction, but
rreversibly damage the endothelium at supramicellar
oncentrations (24).
As shown in Figure 6, vasodilator responses to acetyl-
holine, but not sodium nitroprusside, were significantly
nhibited in arteries incubated with LPC compared with
ontrol.
Treatment of arteries with apo A-IM/DMPC complex
nhanced the dilator response to acetylcholine up to levels
tatistically indistinguishable from the response seen in
ontrol (LPC), thereby implying a significant attenuation
f LPC-induced impairment of endothelium-dependent
asodilation; Apo A-IWT/DMPC complex as well as
lasma-derived HDL produced a nonsignificant attenua-
ion. Neither free apo A-IM nor DMPC alone had any
ignificant effects on LPC-induced endothelial dysfunction.
imilar to previous observations (17), dilator responses in
rteries with intact endothelial function (LPC) were
naffected by treatment (data not shown). Quiescent diam-
ter of carotid arteries was not significantly affected by
ncubation with LPC alone. Also, vasoconstrictor responses
o phenylephrine were unaffected by incubation with LPC
r coincubation with LPC plus treatment agents (data not
el) and acetylcholine (1 M)-induced maximal vasodilator responses (right
05 vs. ApoE, analysis of variance. A significant inverse correlation between
lcholine was observed (Pearson’s r  0.88, p  0.05). DPPC t pan
 0.
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Apolipoprotein A-IMilano and Endothelial Function September 15, 2004:1311–9hown). These data suggest negligible effects of LPC on
asal vascular tone in this vascular reactivity model.
ISCUSSION
he major finding in this study is that administration of
ecombinant apo A-IM complexed with phospholipid mark-
dly prevented impairment of endothelium-dependent va-
odilator response in a murine model of hypercholesterol-
mia and atherosclerosis. The improvement in endothelial
unction with apo A-IM correlated with a reduction in aortic
issue cholesterol content, and was associated with reduced
latelet aggregability. These effects were evident despite
ersistent and severe circulating hypercholesterolemia. Nei-
her free protein nor phospholipid alone produced signifi-
ant effects, thereby suggesting the critical role of the
polipoprotein-PC in mediating the protective effects of
econstituted HDL. Finally, based on rabbit carotid artery
xperiments, the protective effects of apo A-IM on
ndothelium-dependent vasodilation were more pro-
ounced than apo A-IWT or plasma-derived HDL.
The present findings extend our previously described
asculoprotective effects of recombinant apo A-IM/PC,
hich include inhibition of neointimal lesions in balloon-
njured ileofemoral arteries of hypercholesterolemic rab-
its (11), reduced progression and induction of regression
f aortic atherosclerosis in hypercholesterolemic apo
-deficient mice (12,13), and inhibition of restenosis after
oronary stenting in swine (16). Taken together with the
ntiproliferative (15) and antithrombotic (17) effects dem-
igure 5. Bar graphs showing concentration-dependent (upper left) and ti
ysophosphatidylcholine (LPC) on dilator responses to acetylcholine (1 M
M LPC (left panel) and 100 M LPC (right panel). Values (mean 
reconstricted diameter of 2.0  0.1 mm. *p  0.001 vs. control; analysisnstrated by other investigators, these experimental obser-ations illustrate the potential therapeutic benefit of recom-
inant apo A-IM in patients with atherothrombotic vascular
isease.
Endothelial function is an important regulator of vascular
one, inflammation, and hemostasis. Hypercholesterolemia
ay contribute to high coronary heart disease risk by
nducing endothelial dysfunction, which plays a key role in
he pathogenesis of atherosclerosis and its complications.
esides elevated low-density lipoprotein, low HDL has also
een implicated in the high coronary heart disease risk
ssociated with hypercholesterolemia. Low plasma HDL
oncentration has been reported to be an independent
redictor of endothelial dysfunction (5,6). Moreover, eleva-
ion of plasma HDL levels by drug treatment (25) or
nfusion of synthetic HDL using apo A-IWT/PC complex
26) leads to a significant improvement of impaired endo-
helial function. Taken together, these findings suggest a
rotective role of HDL against the development of endo-
helial dysfunction.
The precise cellular or subcellular mechanism by which
po A-IM/PC restored endothelial function in our study is
ot fully understood. First, our current and previous data in
ice (12,13) indicate that treatment with apo A-IM/PC
ay accelerate reverse cholesterol transport in vivo as
videnced by depletion of aortic cholesterol/lipid content.
nhancement of reverse cholesterol transport may be suffi-
ient to rapidly ameliorate the major sequelae of hypercho-
esterolemia including endothelial dysfunction, platelet hy-
erreactivity, and atherosclerosis.
ependent (upper right) effects of incubation of rabbit carotid arteries with
e bottom panels show restoration of dilator responses after washout of 50
, n  4 to 5) are percent change from a phenylephrine (1 M)-induced
riance.me-d
). Th
SEMSecond, a direct effect on endothelial function via mod-
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September 15, 2004:1311–9 Apolipoprotein A-IMilano and Endothelial Functionigure 6. (A) Line plots showing concentration response to acetylcholine in arteries incubated with and without lysophosphatidylcholine (LPC) (50 M)
or 30 to 45 min under different treatment conditions—control, reconstituted high-density lipoprotein (HDL) using apo A-IMilano (apo A-IM/DMPC),
po A-Iwild-type (apo A-IWT/DMPC), plasma-derived HDL, free apo A-IMilano without DMPC (apo A-IM), and DMPC alone. A concentration of 1
g/ml based on protein was used for all preparations. The concentration of DMPC was based on a protein:phospholipid 1:3 molar ratio. (B) Bar graphs
howing maximal dilator response to acetylcholine (top panel) and sodium nitroprusside (bottom panel) in rabbit carotid arteries under different treatment
onditions. Values (mean  SEM) are percent change from a preconstricted diameter of 1.9  0.1 mm. p values are based on comparisons before and after
ncubation with LPC. Open bars  LPC (50 M); solid bars  LPC (50 M). *p  0.005 vs. control  LPC.
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Apolipoprotein A-IMilano and Endothelial Function September 15, 2004:1311–9lation of production or bioactivity of endothelium-derived
actors, such as nitric oxide (EDNO) is also likely. Recent in
itro studies have suggested that HDL can enhance expres-
ion (25) and promote activation of eNOS (27), the rate-
imiting enzyme for synthesis of EDNO. In vivo studies
rovide additional support to the concept that HDLs
revent endothelial dysfunction by promoting endothelial
itric oxide production (25). Most recently, intravenous
nfusion of apo A-IWT/PC in hypercholesterolemic subjects
apidly restored the altered endothelium-dependent vasodi-
ation by increasing nitric oxide bioavailability (26). Lack of
ffect on dilator responses in rabbit carotid arteries with
reserved endothelial function are consistent with previous
bservations (17) and suggest that the protective effect of
DL appears in large part mediated by reversal of the
uppressive effect of oxidized low-density lipoproteins or
PC on EDNO bioavailability.
Third, oxidized low-density lipoproteins are potent in-
ucers of endothelial dysfunction, and there is evidence that
he protective effects of HDL on endothelial function may
e attributable, in part, to its capacity to neutralize the
dverse effects of oxidized low-density lipoprotein. High-
ensity lipoprotein has been shown to inhibit the oxidation
f low-density lipoprotein (28,29). High-density lipopro-
ein can block harmful effects of oxidized low-density
ipoprotein on endothelial cells via sequestration of oxidized
ipids such as LPC from low-density lipoprotein (30) as well
s prevention of its infiltration into vascular tissue (31),
hereby limiting the inhibitory effect on endothelial func-
ion. The inhibitory effects of HDL have been attributed to
ts antioxidant effects via the binding of prooxidant transi-
ion metals by apo A-I and to paraoxonase and platelet-
ctivating factor acetylhydrolase (32).
Our findings in rabbit arteries incubated with LPC
orroborate previous observations (19,30,31) and also pro-
ide evidence for the first time for enhanced protective
ffects of reconstituted HDL using the recombinant apo
-IM compared with apo A-IWT or plasma-derived HDL.
he cysteine-for-arginine substitution at position 173 in the
mino acid sequence of recombinant apo A-IM results,
mong other changes, in a higher antioxidant effect (33) and
inetic affinity for lipids and an easier dissociation from
ipid/protein complexes (34), which might contribute to its
ncreased efficiency for uptake of tissue lipids and cholesterol
fflux (12–14), greater inhibitory effect on neointimal lesions
n balloon-injured rabbit arteries (11), and augmented
revention of endothelial dysfunction compared with apo
-IWT or HDL.
The fact that protective effects of apo A-IM/PC on
ndothelial and platelet function were observed despite the
ersistence of hypercholesterolemia is concordant with pre-
ious observations and indicates that the effects are not
ediated by a major reduction in severity of hypercholes-
erolemia. Consistent with previous observations (11–13),
he current findings also confirm that, for optimal vascular
iological effects, apo A-IM complexed with phospholipid isssential compared with free protein or phospholipid alone.
owever, in the present study, phospholipid alone had a
odest, but nonsignificant, effect in reducing aortic tissue
holesterol content and improving endothelium-dependent
ilator function in mice, but not in rabbit arteries. Because
nhanced reverse cholesterol transport by phospholipid
iposomes is facilitated by HDL, modest effects of DPPC
lone may have resulted from the low endogenous HDL
evels in apo E-null mice in a manner consistent with the
roposed model of HDL-mediated cholesterol efflux (35).
his is supported by our previous observations of a transient
ncrease in plasma-unesterified cholesterol levels (reflecting
obilization of tissue cholesterol) with DPPC treatment
lone (13). The lack of an effect of treatment with phos-
holipid alone in rabbit arteries is due to the fact that
rteries were treated in vitro with DMPC with no potential
ource of apo A-I available to form an HDL complex. In
ontrast, studies have shown regression of fatty streaks in
abbits (36) and marked improvement in endothelial func-
ion in apo E-null mice treated with high-dose
hospholipid-liposomes alone (37). It is likely that differ-
nce in properties and dose of the phospholipid-liposomes
ay account for the contrasting findings.
The inhibitory effects on platelet aggregation in ApoE
ice are consistent with previous in vitro observations in
ats by Li et al. (17). The underlying mechanism is likely
elated to alterations in platelet membrane function, includ-
ng stimulation of NO synthase (38), resulting from lipid
uxes induced by apo A-IM/PC.
otential clinical implications. Although lipid modifica-
ion therapy favorably alters endothelial dysfunction, plate-
et hyperreactivity, and atherosclerotic plaque burden asso-
iated with hypercholesterolemia, such changes occur after
onths and years of therapy. By rapidly mobilizing vessel
all lipids, recombinant apo A-IM has the potential to exert
hese beneficial effects in the short-term, thereby providing
promising therapeutic strategy for acute stabilization of
nstable coronary heart disease.
eprint requests and correspondence: Dr. Sanjay Kaul, Division of
ardiology, Cedars-Sinai Medical Center, 8700 Beverly Boulevard,
os Angeles, California 90048. E-mail: kaul@cshs.org.
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